Oncoinvent appoints Dr. Zuzana Jiráková Trnková as Chief Medical Officer to lead Phase 3 preparations for Radspherin®
- Dr. Jiráková Trnková brings more than 20 years of clinical development experience from Bayer, BioNTech, and Highlight Therapeutics, with expertise spanning global pivotal Phase III trials and alpha-emitting radiopharmaceuticals
Oslo, Norway – 28 October 2026 – Oncoinvent ASA (OSE: ONCIN), a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced the appointment of Zuzana Jiráková Trnková, MD, PhD, as Chief Medical Officer, effective November 4, 2026. Dr. Jiráková Trnková succeeds Kari Myren, who will leave Oncoinvent to pursue a new opportunity outside drug discovery.
